Item 2.02 Results of Operations and Financial Condition.On January 8, 2024, 10x Genomics, Inc. (the Company) issued a press release announcing the Companys preliminary fourth quarter and full year revenue for the period ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1.The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.